At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 72 enrolled
Drug / intervention
MK-6194 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Dose Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-6194 in Participants With Moderate to Severe Atopic Dermatitis
In Brief
A Phase 1 clinical trial evaluating MK-6194 and Placebo for Dermatitis, Atopic. Completed, enrolled 72 participants across 19 sites in 6 countries.
Detailed Summary
The primary objective of this study is to characterize the safety and tolerability of MK-6194 following multiple doses among participants with moderate to severe atopic dermatitis who are unresponsive to other therapies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDermatitis, Atopic
CountriesBelgium, Bulgaria, Canada, Romania, Spain, United States
Collaborators--
Timeline
Phase 1CompletedFinished
2023202420252026
First PostedJul 2022
Enrollment StartAug 2022
Primary CompletionMay 2024
TodayJul 2026
First PostedJul 8, 2022
Enrollment StartAug 8, 2022
Primary CompletionMay 22, 2024
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 4.0 years ago
Interventions
MK-6194biological
MK-6194 administered subcutaneously (SC)
Placebobiological
Placebo comparator to MK-6194 administered SC